Bora Lim

7.5k total citations · 2 hit papers
153 papers, 3.8k citations indexed

About

Bora Lim is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Bora Lim has authored 153 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Oncology, 65 papers in Cancer Research and 42 papers in Molecular Biology. Recurrent topics in Bora Lim's work include Breast Cancer Treatment Studies (42 papers), HER2/EGFR in Cancer Research (41 papers) and Cancer Genomics and Diagnostics (22 papers). Bora Lim is often cited by papers focused on Breast Cancer Treatment Studies (42 papers), HER2/EGFR in Cancer Research (41 papers) and Cancer Genomics and Diagnostics (22 papers). Bora Lim collaborates with scholars based in United States, South Korea and Japan. Bora Lim's co-authors include Naoto T. Ueno, Wendy A. Woodward, Puneet Singh, James M. Reuben, Xiaoping Wang, Nicholas E. Navin, Yiyun Lin, Gabriel N. Hortobágyi, Maarten Slagter and S.-Y. Lin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature reviews. Cancer.

In The Last Decade

Bora Lim

136 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

2021 672 citations Bora Lim, Naoto T. Ueno et al. Annals of Oncology profile →
Targeting Apoptosis in Cancer

2022 148 citations Bora Lim et al. profile →

Peers

Countries citing papers authored by Bora Lim

Since Specialization

Citations

This map shows the geographic impact of Bora Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bora Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bora Lim more than expected).

Fields of papers citing papers by Bora Lim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bora Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bora Lim. The network helps show where Bora Lim may publish in the future.

Co-authorship network of co-authors of Bora Lim

This figure shows the co-authorship network connecting the top 25 collaborators of Bora Lim. A scholar is included among the top collaborators of Bora Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bora Lim. Bora Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NF1-depleted ER ⁺ breast cancers are differentially sensitive to CDK4/6 inhibitors 2025 ·Science Translational Medicine ·(unknown), (unknown), Eric J. Jaehnig, Meenakshi Anurag, Jonathan T. Lei, Long Feng, Chenwei Wang, (unknown), Purba Singh, (unknown), (unknown), Craig T. Vollert, (unknown), Xi Chen, Yi Li, Bora Lim, Alastair M. Thompson, Shunqiang Li, Charles E. Foulds, Bing Zhang, Matthew J. Ellis, Eric C. Chang	0
2	Development of a Novel Biomarker Platform for Profiling Key Protein–Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs 2025 ·Cancers ·(unknown), (unknown), (unknown), (unknown), Bora Lim, Stephanie J. Bouley, James A. Walker, Erinna F. Lee, W. Douglas Fairlie, Kevin R. Kelly, (unknown)	1
3	Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity 2024 ·Journal for ImmunoTherapy of Cancer ·Daisuke Morita, Amanda Rosewell Shaw, Greyson Biegert, Caroline E. Porter, Mae Woods, Spyridoula Vasileiou, Bora Lim, Masataka Suzuki	1
4	Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness 2023 ·Science Advances ·(unknown), (unknown), (unknown), Aloran Mazumder, (unknown), (unknown), (unknown), (unknown), (unknown), Jonathan T. Lei, Bora Lim, Susan E. Waltz, Shreya Raghavan, Matthew N. Bainbridge, Svasti Haricharan	10
5	Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients 2023 ·Cancers ·Evan N. Cohen, Gitanjali Jayachandran, Hui Gao, (unknown), (unknown), (unknown), (unknown), Juhee Song, Yu Shen, Jie Willey, Bora Lim, Vicente Valero, Naoto T. Ueno, James M. Reuben	10
6	Breast Cancer With a HER2 FISH Group 2 Result: Should HER2 Tests be Repeated? 2023 ·Clinical Breast Cancer ·Minhua Wang, Qingqing Ding, (unknown), (unknown), Lei Huo, Zhenya Tang, Hongxia Sun, (unknown), Guilin Tang, Bora Lim, Yun Wu, Constance T. Albarracin, Ayşegül A. Şahin, Hui Chen	2
7	Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer 2020 ·Cancers ·Kumiko Kida, Kenneth R. Hess, Bora Lim, Toshiaki Iwase, (unknown), Vicente Valero, Anthony Lucci, (unknown), Wendy A. Woodward, Savitri Krishnamurthy, Gabriel N. Hortobágyi, Debu Tripathy, Naoto T. Ueno	1
8	Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery? 2020 ·Annals of Surgical Oncology ·Lauren M. Postlewait, Mediget Teshome, Sarah M. DeSnyder, Bora Lim, Henry M. Kuerer, Isabelle Bedrosian, Wendy A. Woodward, Naoto T. Ueno, Anthony Lucci	12
9	A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer 2020 ·The Oncologist ·Bora Lim, Juhee Song, Nuhad K. Ibrahim, Kimberly B. Koenig, Mariana Chávez‐MacGregor, Joe Ensor, (unknown), Savitri Krishnamurthy, Abigail S. Caudle, Simona F. Shaitelman, Gary J. Whitman, Vicente Valero	5
10	A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer 2020 ·Investigational New Drugs ·Clinton Yam, Gaiane M. Rauch, (unknown), Meghan Karuturi, Elizabeth E. Ravenberg, Jason B. White, (unknown), (unknown), (unknown), Bora Lim, Jennifer K. Litton, (unknown), Sadia Saleem, James Stec, W. Fraser Symmans, Lei Huo, Senthil Damodaran, Ryan Sun, Stacy L. Moulder	24
11	HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features 2019 ·Human Pathology ·Qingqing Ding, Hui Chen, Bora Lim, Senthil Damodaran, Weiwei Chen, Debu Tripathy, Sarina A. Piha‐Paul, Rajyalakshmi Luthra, Funda Meric‐Bernstam, Ayşegül A. Şahin	12
12	Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer 2017 ·Clinical Cancer Research ·(unknown), Jangsoon Lee, Takahiro Kogawa, Peter Ordentlich, Debu Tripathy, Bora Lim, Naoto T. Ueno	40
13	ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms 2017 ·Molecular Cancer Therapeutics ·Marie D. Ralff, C. Leah B. Kline, (unknown), Jessica Wagner, Bora Lim, David T. Dicker, Varun V. Prabhu, Wolfgang Oster, Wafik S. El‐Deiry	38
14	MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer 2017 ·Biochemical and Biophysical Research Communications ·(unknown), Masayuki Wakabayashi, (unknown), (unknown), (unknown), (unknown), Atsuko Ishida, Jangsoon Lee, Bora Lim, Naoto T. Ueno, Hideki Ishihara, Takashi Inui	9
15	A Case Report of a Delayed Vascular Chorea Patient Treated with Sukjihwangbogan-tang-gagam 2016 ·The Journal of Internal Korean Medicine ·(unknown), (unknown), Bora Lim, (unknown), (unknown), (unknown)	1
16	Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease 2016 ·Annals of Oncology ·Stacy L. Moulder, Jennifer K. Litton, EA Mittendorf, Wei Yang, Naoto T. Ueno, Kenneth R. Hess, Vicente Valero, Rashmi K. Murthy, Nuhad K. Ibrahim, Bora Lim, Banu Arun, Alan J. Thompson, Helen Piwnica‐Worms, Debu Tripathy, W. Fraser Symmans	1
17	Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10 2015 ·Cancer Research ·Joshua E. Allen, Varun V. Prabhu, Mala K. Talekar, A. Pieter J. van den Heuvel, Bora Lim, David T. Dicker, Jennifer L. Fritz, (unknown), Wafik S. El‐Deiry	35
18	A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus 2015 ·Molecular Cancer Therapeutics ·(unknown), Sijie Hao, Shuwen Wang, Yuanjun Zhao, Bora Lim, (unknown), David J. Spector, Wafik S. El‐Deiry, Si-Yang Zheng, Jiyue Zhu	18
19	Buxus Microphylla var. Koreana Nakai Extract for the Treatment of Gastric Cancer 2013 ·Journal of pharmacopuncture ·Hee Jung Lee, Min Chul Kim, Bora Lim, Byung Joo Kim	6
20	Modulation of Pacemaker Potentials by Pyungwi-San in Interstitial Cells of Cajal from Murine Small Intestine - Pyungwi-San and Interstitial Cells of Cajal - 2013 ·Journal of pharmacopuncture ·Jung Nam Kim, (unknown), Bora Lim, Young Kyu Kwon, Byung Joo Kim	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact